Belvedere Trading
ITOS

Belvedere Trading’s iTeos Therapeutics ITOS Stock Holding History

Belvedere Trading’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-22,601
Closed -$231K – 938
2024
Q3 		$231K Buy
22,601
+8,843
+64% +$135K ﹤0.01% 329
2024
Q2 		$204K Buy
+13,758
New +$197K ﹤0.01% 350

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Belvedere Trading's ITOS Position: Q4 2024 in Review

Belvedere Trading sold out of iTeos Therapeutics (ITOS) in Q4 2024, closing a stake of 22,601 shares — an estimated $231K sold.

Belvedere Trading first reported a position in ITOS in Q2 2024 and held it in 2 quarters. The position peaked at $231K in Q3 2024. 136 funds tracked by Wall St. Rank hold ITOS as of Q4 2024.

  • Belvedere Trading reported no remaining iTeos Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Belvedere Trading sold 22,601 iTeos Therapeutics shares in Q4 2024, an estimated $231K.
  • Belvedere Trading first reported a position in iTeos Therapeutics in Q2 2024 and held it in 2 quarters.
  • Belvedere Trading's iTeos Therapeutics position peaked at $231K in Q3 2024.
  • 136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2024.

Based on Belvedere Trading's 13F filing for Q4 2024, filed 31 Jan 2025.